Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Vanda Pharmaceuticals
Study ID
NCT03838926
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Relapsed or Refractory Hematologic Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Trichostatin A — DRUG
    Intravenous Infusion

Study Details

The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.

Key Dates

Start date
Sep 27, 2018
Status verified
Mar 2026
Primary completion
Dec 31, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
42 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Trichostatin A

Primary Outcome Measure

Safety and tolerability of trichostatin A measured by spontaneous reporting of adverse events (AEs) [ Time Frame: Up to 24 months ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Vanda Investigational SiteWashington D.C.District of Columbia20007-
Vanda Investigational SiteLafayetteIndiana47905-
Vanda Investigational SiteHackensackNew Jersey07601-
Vanda Investigational SiteSeattleWashington98109-

Find similar trials in Washington D.C., DC

By research site
Vanda Investigational Site· Washington D.C., DCVanda Investigational Site· Lafayette, INVanda Investigational Site· Hackensack, NJVanda Investigational Site· Seattle, WA